Synthetic peptide, incretin-receptor agonist

Tirzepatide

Also catalogued as LY3298176, LY-3298176.

CAS number: 2023788-19-2
Molecular formula: C225H348N48O68
Molecular weight: 4813.45 g/mol
PubChem CID: 156588324

Identity

CAS number: 2023788-19-2
Molecular formula: C225H348N48O68
Molecular weight: 4813.45 g/mol
Residues: 39
PubChem CID: 156588324

An engineered 39-residue sequence containing two aminoisobutyric-acid residues and a C20 fatty-diacid attachment at position 20; a plain one-letter rendering would misstate it.

What it is

Tirzepatide (developed under the code LY3298176) is a synthetic peptide of thirty-nine residues based on the sequence of glucose-dependent insulinotropic polypeptide (GIP). The design incorporates two aminoisobutyric-acid residues and a C20 fatty-diacid moiety attached through a linker to the lysine at position 20.

In the primary literature it is characterised pharmacologically as a dual agonist of the GIP and GLP-1 receptors. Its discovery and characterisation were published by Coskun and colleagues in 2018.

Regulatory status

Tirzepatide is the active ingredient of prescription products approved by the U.S. FDA, first in May 2022 (Mounjaro). The research material listed here is not those products and is not a drug.

Primary literature

Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism 2018;18:3–14.
PMID 30473097

Citation titles are reproduced verbatim from the journal record. A citation documents the molecule's published identity and history; it is not a claim about the material sold here.